End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3

Slides:

Advertisements

Similar presentations

Management of Diabetes Treat to Target Approach (A1c

Advertisements

STRADIVARIUS Effect of Rimonabant on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Stephen J. Nicholls.

Rimonabant: A new approach to multiple cardiometabolic risk factors Version April 2005.

Definitions Body Mass Index (BMI) describes relative weight for height: weight (kg)/height (m 2 ) Overweight = 25–29.9 BMI Obesity = >30 BMI.

Table 1 Children who ate presweetened RTEC had lowest %overweight & obesity Anthropometric Parameter Breakfast Skipper Presweetened RTEC Non-presweet RTECOB.

Smoking Cessation in Smokers Motivated to Quit Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Robert Anthenelli.

A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.

Women and Cholesterol What You Need to Know. Age: 45 Women and Cholesterol: What You Need to Know HDL: 60 mg/dL and above LDL: Below 100 mg/dL GoodBad.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

RETNUH HEALTH CARES PRO-ACTIVE OR RE-ACTIVE BE-ACTIVE.

Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.

Rimonabant in Obesity Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Jean-Pierre Despres RIO LIPIDS Trial.

METABOLIC SYNDROME From PubMed Health A service of the National Library of Medicine, National Institutes of Health. A.D.A.M. Medical Encyclopedia, Atlanta,

Treatment with medical waters in Hungary prof. L. Halmy Hungary.

© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.

Farid Saad Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.

SATURN: Objective To compare the effects of rosuvastatin 40 mg versus atorvastatin 80 mg on progression of coronary atherosclerosis assessed by intravascular.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

HDL LowLess than 40 mg/dL High60 mg/dL and above LDL OptimalLess than 100 mg/dL Near Optimal mg/dL Borderline High mg/dL High mg/dL.

Diabetes and High Blood Pressure Are Like Twins. Ignoring Your High Blood Pressure.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Scientific Notation. Write the following numbers in scientific notation: Ex:3,700,000 km ___________________________ Ex: g ________________________.

Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:

 In 2003, the USPSTF recommended that clinicians screen adults for obesity and offer intensive counseling and behavioral interventions to promote weight.

From ESH 2016 | LB 3: Davide Agnoletti, MD

Baseline characteristics and effectiveness results

RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR

HbA1c 1245_0025final study-report-body. Table : 1 HbA1c (%) change from baseline MMRM results over time − FAS (OC−AD)

ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.

Supplementary material

Copyright © 2012 American Medical Association. All rights reserved.

Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults Risks and Assessment NHLBI Obesity Education.

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

The ASSERT Study.

End point Muraglitazar 5 mg plus metformin (n=569)

University of Alaska Win Utilization report 7/1/2011 to 6/30/2012

Placebo group 5-mg rimonabant group p 20-mg rimonabant group

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

WELLNESS WELLNESS REWARDS Wellness Program

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Time point Difference in systolic BP (mm Hg) p

VALUE: New-onset diabetes in an amlodipine-based vs valsartan-based therapy in high-risk hypertensives Diagnostic criteria Valsartan n (%) Amlodipine n.

Level of risk factor control in the overall sample and by gender

Comparison of clinical and functional parameters among non-responders (=1) and responders (≥4) among healthy elderly and elderly patients with T2DM. Comparison.

Cigarette smoke alters chylomicron metabolism in rats

OmniHeart Feeding Study

Trial profile Luc F Van Gaal, Lancet 2005;365:1389.

Flow of Patients Through Trial

Comparison of clinical and functional parameters between the CMV+ and CMV− participants in the healthy elderly and elderly patients with T2DM. Comparison.

(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.

Change in (A) total cholesterol; (B) LDL-cholesterol; (C) HDL-cholesterol and (D) triglycerides over 5 years in response to 12-week intensive lifestyle.

Relative risk of a major coronary heart disease event (myocardial infarction incidence, fatal coronary heart disease, or coronary revascularization) for.

PROSPER: trial design

TNT diabetes analysis: Baseline and final LDL cholesterol levels

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

Change in markers of glycometabolism and cardiovascular risk profile.

Percentage of patients with type 2 diabetes with A1C < 7% (n = 248), blood pressure > 130/80 mmHg (n = 248), and LDL cholesterol < 100 mg/dl (n = 207)

Prevalence of high SAT or high VAT by BMI category in women (A) and men (B) and by waist circumference category in women (C) and men (D). Prevalence of.

Correlation between progranulin (dependent variable) and CKD stage adjusted for age and sex, as well as DBP, WHR, triglycerides, HDL cholesterol, LDL cholesterol,

III. Treating dyslipidemias

This pooled data from 11 prospective cohort studies with 650,386 white adults found a significant correlation in all-cause mortality when waist circumference.

DPP4 release of explants obtained from adipose tissue of lean controls and obese patients before and after bariatric surgery, and linear correlation with.

Effect of empagliflozin on efficacy parameters at week 18.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

© The Author(s) Published by Science and Education Publishing.

Differences in changes in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides (expressed as mg/dL) between patients with hyperlipidaemia.

Presenting Author: Emileigh L. Willems

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Changes in weight and waist size in the rimonabant- and placebo-treated groups End point Rimonabant 20 mg (n=339) Placebo (n=348) p Weight (kg) -5.3 -1.4 <0.001 Waist circumference (cm) -5.2 -1.9 Scheen A. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.

HDL cholesterol and triglyceride parameters in the rimonabant- and placebo-treated groups End point Rimonabant 20 mg (n=339) Placebo (n=348) Percent difference (compared with placebo) p Change in HDL cholesterol (mg/dL) 6.6 2.7 8.4 <0.001 Change in triglycerides (mg/dL) -31.2 3.6 16.4 Scheen A. American Diabetes Association 2005 Scientific Sessions; June 10-14, 2005; San Diego, CA.